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1. Introduction 
Cartilage tissue has only one cell type, the chondrocyte, wich is immerse in extracellular 
matrix composed mainly by collagen type II. Because of such properties, cartilage tissue 
doens’t heal spontaneously after a lesion, which with time becomes progressive and chronic. 
Cartilage lesions may be caused by automobile and sport accidents, as well as by normal 
wear due to age, and usually generate severe pain and difficulty of mobility in patients. 
Therefore, cartilage disease is a common type of lesion to which everyone is susceptible and 
represents a very important public health problem in the world (Willians et al, 2006). 
Initial therapies to treat cartilage lesions included replacement surgery with artificial or 
natural organs and tissue grafts. Artificial and natural organ transplants and tissue grafts, 
on the other hand, are able to fully replace organs or tissues, but require continuous and 
permanent immune therapy to reduce immunological response to graft and to increase the 
longevity of transplanted tissue. Therefore, although major progresses were done in the 
field of cartilage tissue regenerative medicine during the years, current therapies still 
present limitations. Moreover, no adequate cartilage substitute has been developed. Thus, 
most of the severe injuries related to cartilage are still unrecoverable or not adequately 
treated. Therefore, these methods are helpful but need modification to develop better novel 
or alternative therapies (Ikada et al, 2006 and Tabata et al, 2009).  
In such context emerges tissue engineering, which has been defined by Langer and Vacanti 
as: ‘‘an interdisciplinary field of research that applies the principles of engineering and the 
life sciences towards the development of biological substitutes that restore, maintain, or 
improve tissue function” (Salgado et al, 2004).  
Tissue Engineering or Bioengineering is based on three elements: (i) cells; (ii) scaffolds and 
(iii) signalling molecules. These elements integrate themselves and promote the new tissue 
development (Langer and Vacanti, 1993; Ikada et al, 2006 and Chiang et al, 2009). In order to 
mimic tissue structure, tissue engineering also requires 3 dimensional cell cultures, which, in 
contrast to traditional bidimensional cell culture, has only been developed recently. 
Nowadays, it is beyond dispute that this cell culture strategy presents many advantages, 
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including continuous exchange of nutrients and oxygen, metabolite removal and mechanical 
and chemical stimuli. All these factors allow and facilitate cell differentiation and 
proliferation (Ikada et al, 2006 and Tabata et al, 2009). 
Used as scaffolds to 3D cultures, biomaterials studied in tissue engineering can be derived 
from natural or synthetic sources and may belong to one of three classes: metals, ceramics, 
or polymers. Once transplanted, biomaterials can be reabsorbed in vivo and replaced by 
new tissue (Ikada et al, 2006 and Tabata et al, 2009).  
1.1 Cells 
Tissue engineering strategy demands high numbers of cells, therefore, ideal cell sources for 
tissue engineering application must be easily isolated, expandable to higher passages, be 
non-immunogenic and have a protein expression pattern similar to the tissue regenerated 
(Salgado et al, 2004).  
Chondrocytes derived from autologous tissue constitutes the most obvious choice to be used 
in tissue engineering, for their absence of immunogenicity and possibility of limited 
expansion in vitro. However this methodology suffers from many limitations, such as the 
generation of a second site of cartilage lesion, as well as the limited amount of cells obtained 
at the end of the procedure.  
As an alternative, stem cells present a great therapeutic potential due to their capacity of 
differentiation to many cell lineages. These cells are able to self-renew and proliferate for 
long periods in vitro (Zuk et al, 2002 and Mountford et al, 2008).  
Stem cells are divided into two great classes: adult and embryonic stem cells and also 
divided based on their differentiation potential. even though they may also be described 
based on their differentiation potential. According to this latter classification, the zygote and 
the cells produced by its first two divisions are considered totipotent, or capable of 
generating any cell of the embryo as well as the trophoblast. Continuing the embryo 
development, at the fifth day the embryo is constituted of two cell types, which compose the 
trophectoderm and the inner cell mass. Cells from the inner cell mass (ICM) are also called 
embryonic stem cells and are classified as pluripotent, for their capacity of generating the 
three embryo germ lines. ICM cells are not totipotent because they lack the capacity to 
generate extra-embryonary tissues. Later in the development, present in fully differentiated 
tissues, there are multipotent stem cells, which present more limited differentiation 
potential, being restricted to generate cells from the same embryonary origin as the tissue 
where they are found. However, according to the literature, multipotent stem cells may 
present a broader differentiation capacity then initially expected (Friedenstein et al, 1966; 
Owen et al, 1988; Zuk et al, 2002 and Conrad et al, 2004). 
In 2007 yet a another type of stem cell was generate in vitro, the induced Pluripotency Stem 
Cell (iPSC). This new type of cells is produced by reprogramming adult cells, such as 
fibroblasts to a pluripotent state similar to that observed in embryonic stem (ES) cells, by 
retroviral transduction of  some  genes (Nanog, Oct4, Sox2, c-Myc, Klf 4 and Lin 28). The 
forced expression of such genes was capable of giving differentiated adult cells pluripotent 
differentiation capacity akin to the embryonic stem cell. This technique was termed cellular 
reprogramming (Takahashi et al, 2006; Yu et al, 2008 and Yamanaka et al, 2009).  
It is important to aknowledge each stem cell type properties, for all stem cell types present 
inherent advantages and disadvantages, depending on their application.  
Among adult stem cells there are: 
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 Mesenchymal stem cells (MSCs), which take part of the mesenchyme of varied tissues 
such as the bone marrow, adipose tissue, brain, dental pulp and skin, and are capable of 
differentiating into many cell lineages. MSCs present great potentials to the treatment of 
several diseases due to their low immunogenicity, immunomodulatory properties, the 
possibility of autologous transplantation, easy isolation and in vitro proliferation 
possibility.  
 The bone marrow was the first source of MSCs described in the literature, and still remains 
the more thoroughly studied stem cell type. Also present in the bone marrow, there are: 
 Hematopoietic stem cells (HSCs), which differentiate into all the hematopoietic and 
lymphoid cells from the blood. Therefore, HSCs are studied due to their roles in 
leukemia and other blood diseases. Usually, the treatment of such diseases include the 
substitution of the sick bone marrow to a healthy one, and in accordance to such fact, 
studies involving HSCs are mainly focused on how HSCs behave in different live 
organisms. Autologous grafts, or the implantation into a genetically similar live 
organism, may be performed in order to treat blood related diseases, as well as 
heterologous implantations, or grafting into genetically different live organisms. 
Presently, these different graft types show paradox behaviours. Heterologous grafts 
cause immune rejection in the host, requiring the host to be continuously submitted to 
immunossuppression.  This therapy can lead to patient death due to the absence of an 
immune response to opportunist pathogens, however, this treatment is still commonly 
used today. In cases where the patient’s conditions are good, cells can be extracted from 
the patient himself. This method is named autologous transplantation and is not 
susceptible to host rejection (Friedenstein et al, 1966; Owen et al, 1988, Conrad et al, 
2004; Davila et al, 2004 and Gregory et al, 2005).  
Even though stem cells derived from bone marrow have been well studied, they do not 
constitute the ideal mesenchymal stem cell source, due to the limited extent of MSC 
isolation (low extractable quantity of tissue) and donor discomfort. Therefore, new 
alternative sources have been proposed, including the adipose tissue. Adipose tissue is an 
excellent tissue to obtain great quantities of mesenchymal stem cells and it presents low 
discomfort when compared to bone marrow. According to Zuk, 2002, adipose tissue is a 
viable source to obtain mesenchymal stem cells, and these cells present similar 
characteristics to bone marrow MSCs.  
Since the discovery of so many MSC sources, the International Society for Stem Cell Therapy 
postulated that a cell will only be considered a MSC if it presents 3 characteristics: 1. Being 
able to attach to cell culture surface; 2. Specific surface antigen expression; 3. Multipotent 
differentiation potential (osteoblast, adipocytes, chondroblasts)  (Dominici et al, 2006). MSCs 
must then be capable of differentiating into cartilage, bone and muscular cell lineages, self-
renewing and proliferating in vitro.  
Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocist and present 
great moral, religious and ethical barriers due to their isolation technique, which leads to 
embryo destruction. They constitute a very promising stem cell type considering the tissue 
engineering field, for their pluripotent differentiation potential and unlimited proliferation 
capacity. Besides their ethical issues, ESCs also present the possibility of when injected in vivo, 
to produce teratomas. Thus, even though ESC present endless wonderful possibilities to be 
used in several science fields, more studies are necessary to ensure their safety and efficiency 
to be used in humans (Takahashi et al, 2006). In 2009, the biotech company Geron received the 
FDA approval to start the first human clinical trial of embryonic stem cell-based therapy in 
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order to assess the safety of using differentiated embryonic stem cells to treat spine cord 
injuries. In 2011, they finally injected the first cells in patients and are waiting for results. 
With respect to the potential of these stem cells, researchers have developed methods to 
trace these cells in both live and post-mortem stages. This is very important, because there 
are many routes and ways to introduce stem cells in an organism. If we can determine 
where these cells are going, wheter they can stay inside the 3D scaffold and differentiate or 
if they can stimulate others cells to migrate and graft, many unanswered questions will be 
addressed. Therefore, researchers have developed tracing techniques to locate injected cells 
in the organism. In basic science models, genetically modified transgenic organisms that 
express fluorescent proteins (FP) have been used to generate cells expressing such markers. 
Green fluorescent protein, the first FP generated, was derived from fluorescent seaweeds 
found in the US. After the isolation and characterization of the protein, its gene was 
introduced in mice and many other animals, so that those animals fluoresce when exposed 
to UV radiation. Cells taken from these transgenic animal and introduced into other non-
transgenic animal (of similar lineages) do not present rejection problems and allow for 
trafficking of these cells (Ogawa et al, 2004). Many other tracing strategies were also 
developed including: radioisotopes, DNA and mitochondria dyes, as well as fluorescent 
microbeads. (Ogawa et al, 2004). 
1.2 Tissue engineering 
Tissue engineering or Bioengineering, as definided by Langer and Vancanti, constitute a 
innovation in regenerative medicine and is based on three elements (i) cells; (ii) scaffold and 
(iii) growth factors. Scaffolds can be bi-dimensional and three-dimensional, bi-dimensional 
structures allow us to observe only cell behavior with reference to medium composition, 
cell-cell interaction, cell viability and cell differentiation. However, three-dimensional 
structures allow us more physiologically realistic factors including dynamic fluids rich in 
O2, mechanical forces, and cell adhesion but this interaction is three-dimensional and can be 
modify cell behaviour. For instance, nowadays it is beyond dispute that scaffolds are 
sources of instructive signals for cell differentiation, migration, proliferation and orientation, 
and of paramount role in phenotype maintenance. Therefore, many studies have searched 
for great biomaterials that can be used as a surrogate for extracellular matrix (ECM) tissue 
(Ikada et al, 2006; Chiang et al, 2009; Tabata et al, 2009 and Mingliang et al, 2011).  
One of the main goals of Tissue engineering is to create a scaffold that can mimic ECM due 
to better cells, and micro-environment interactions. This interaction permits cells adhesion, 
migration, proliferation, differentiation and long-term viability (Bacakova et al, 2004). To 
produce a new organ or tissue we need scaffolds that are biodegradable and biocompatible. 
These structures need stable and appropriate porosity and architecture to permit formation 
of a vascular net able to give nutrients and O2. These scaffolds should be gradually 
degraded to be occupied by new tissue formed by the interaction among the 3D scaffold, 
stem cells and growth factors.  
To construct our 3D structure, we use chitosan and gelatin. Chitosan is derived from chitin 
presents in arthropods, including shrimp and crab. It is a polysaccharide very similar to 
glycosaminoglycans present in cartilage ECM. It is acid soluble, forms like-gel solutions and 
is water insoluble. Therefore, chitosan is available in nature and easily manipulated beyond 
its seemed ECM polysaccharides state (Roughley et al, 2006 and Dong et al, 2010).  
Gelatin is derived from collagen, mainly proteins presents in cartilage ECM. Cartilage tissue 
is composed of type II colagen. In spite of this, gelatin is not composed of type II collagen, it 
present RGD motifs like all types collagen and this motif is able promote cell adhesion and 
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differentiation and/or promote phenotype maintenance. Gelatin is water and acid soluble 
and is able to mix to chitosan gels (Tortelli and Cancceda, 2009 review). Both biomaterials 
have properties similar to cartilage ECM and they are biocompatible and biodegradable and 
are able to form porous where fluid can pass.  
The connection between chitosan and gelatin is termed reticulates. Reticulates have a property 
to make chemical connections between molecules. These connections are stable and require the 
maintenance of stable scaffold architecture. In this study, we used two reticulates: Genipin and 
Glutaraldehyde. These reticulates are used beyond stable architecture, to increase degradation 
time in vivo. The importance of that controllable degradation is that it guarantees new tissue 
formation (e.g. ECM secretion) by differentiated cells. This way, the scaffold is able to provide 
a temporary matrix for developing cells, such as a support for cell attachment and tissue 
neomorphogenesis (Bacakova et al, 2004 and Mironov et al, 2009). 
Glutaraldehyde is the reticulate most used in tissue engineering; it helps the 3D matrix 
creation through freeze and freezing drying.  This process creates pores inside the scaffold 
and these pores are favorable to cell development, adhesion, proliferation and 
differentiation beyond the exchange of metabolites and food (Hofmann et al, 2009). Despite 
being most used, glutaraldehyde presents high levels of citotoxicity and limited reactivity 
with acetylates molecules. Therefore, a new approach is needed to find new reticulate that 
overcome all prior difficulties. 
There is a new reticulate that had been studied, genipin. Genipin is derived from vegetable 
(Gardennia jasminoides, ELLIS) and it presents good capacity to increase mechanical 
properties for biomaterial-based protein. It forms pores and delays degradation that favors 
new tissue formation (Al amar et al, 2009 and Beier et al, 2009). This work verified which 
reticulates are better for our goal, the design of cartilage tissue. 
The ultimate goal of tissue engineering is to design and fabricate close-to-natural functional 
human organs suitable for regeneration, repair and replacement of damaged, injured or lost 
human organs. Without tissue engineering, living functional human organs can be 
produced only during natural embryonic development. Therefore, according of Miranov 
and colleagues (2009) one of the most logical and obvious ways to look for possible 
alternatives to solid biodegradable scaffold-based tissue engineering approaches is to 
understand how tissue and organs are formed during normal embryonic development. 
Organ printing (one biomedical application of rapid prototyping) is an emerging 
transforming biomimetic technology that has potential for surpassing traditional solid 
scaffold-based tissue engineering (Miranov et al, 2009). 
1.3 Signalling molecules 
As the third pillar to tissue engineering, besides cells and scaffolds, it is important to deal 
with media constitution. All biochemical molecules present in culture media are able to 
stimulate cells. These stimuli differentiate all cells in culture, so theses molecules are 
important in creating new tissue or regenerate damage tissue. Due to stem cell 
differentiation capacities, they are cultivated in special medium that stimulates them during 
the differentiation process. Here we describe signaling molecules that stimulate 
chondrogenic differentiation of stem cells, mainly  type II collagen secretion (Raghunath et 
al, 2005). 
There are key molecules to chondrocyte differentiation: TGF-┚ and dexamethasone (Raghunath 
et al, 2005; Betre et al, 2006; James et al, 2007; Melrose et al, 2008 and Mueller et al, 2008). 
According to Lee and colleagues (2004) and Melrose and colleagues (2008), TGF-┚ induces the 
synthesis of type II collagen through Sox-9 pathway. Mueller and colleagues (2008) agree that 
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dexamethasone causes chondrocyte hypertrophy because it induces type X collagen synthesis 
from cells. If this process occurs, the neotissue will suffer mineralization and will lose its 
properties (e.g. smoothness). However, most studies that aim to achieve chondrogenic 
differentiation use such molecules in differentiation medium, as the beneficial aspects outweigh 
disadvantages and such molecules seem to necessary to the chondrogenic differentiation 
process (Otto et al, 2004; Medrado et al, 2006; Huang et al, 2006 and Koay et al, 2007). 
Still considering the example given, one viable option to obtain cartilage tissue in vitro and 
adequate to tissue engineering application is the combination of chitosan and gelatin, 
reticulated either by glutaraldehyde or genipin, seeded with mesenchymal stem cells. Here 
we show in vitro analysys performed to verify stem cell behavior in control (no 
differentiation stimuli) and differentiation medium. We tested whether differentiated cells 
in 3D scaffolds maintained differentiated phenotype in vivo. 
2. Materials and methods 
All animals were used and sacrificed in accordance to CETEA – UFMG (Ethical Committee 
Animals Experiments) # 153/2006. We used 30 rats (Lewis, male and female, 4 to 6 weeks 
old) from Physiology Department of UFMG and 5 rats (Lewis transgenic GFP - Lew-Tg e-
GFP, 4 to 6 weeks old) from Missouri University (USA).  
2.1 Cells and characterization by flow cytometry 
Mesenchymal stem cells were obtained from rat adipose tissue (Lewis and Lewis eGFP).  
Rats were killed with anesthetic overdose and adipose tissue was removed from the 
abdominal region and it was maintained in conical tubes with DMEM supplemented 10% 
serum bovine fetal (SBF). After a few minutes, this tissue was digested with collagenase type 
II for 60 minutes, in 37ºC and 5% CO2. Every 15 minutes this solution was manually shaken. 
After this procedure, this solution was centrifuged for 10 minutes (1400rpm). The pellet was 
recovered and cultivated in DMEM with 10%SBF for 3 days. On the third day, the medium 
was collected, centrifuged to recover the non adherent cells and adhesive cells were 
cultivated in DMEM + 10% SBF. When this culture became confluent (80 to 90%), cells were 
trypsinized and expanded to new culture flasks (Zuk et la, 2002). 
These cells were phenotyped by flow cytometry and used for differentiation studies at the 
4th pass by flow cytometer. This procedure used anti-CDs antibodies to label markers 
present on the cell surface. The CDs are markers present in mesenchymal stem cells, 
hematopoietic stem cells and other cell types. We used CD54, CD91 and CD73 as MSC 
markers and CD45 as HSC (Zuk et al, 2002 and Ucelli et al, 2006). All cells are fixed with 
formaldehyde (2%) and analyzed by FACScalibur (USA). For control, we use only secondary 
antibody and selected the gate for cells to be analyzed we used no marker cells. Around 
20,000 events (minimum) were used for fluorescence capture in Cell Quest software. All 
data were analyzed by WinMid 2.8 software. This procedure was performed according Zuk 
et al, 2002. To conduct flow cytometry we used 1x106 cells and stained with antibodies (anti-
CDs) isolated before we used secondary antibody (FITC for Lewis and PE for Lewis eGFP).  
2.2 Chondrogenic medium 
Chondrogenic medium was based in protocol by Medrado and cols (2006), Huang and cols 
(2006), Koay and cols (2008) and Breyner and cols (2010), from these we used 10µg/L 
recombinant TGF-┚3 (Bioclone), 10-7 M dexamethasone (Sigma) with 1% SBF.  
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2.3 Cell differentiation 
Mesenchymal stem cells were cultivated in T75 flasks with control medium (DMEM + 
10%SBF) and chondrogenic medium for 1, 3, 6 and 9 weeks. To verify to differentiation 
process immunofluorescence was perfomed using antibodies for collagen II, CD54, 
CD90,CD45 and CD73, osteocalcin (Zuk et al, 2002 and Huang et al, 2006).  
2.4 Immuno-fluorescence 
Mesenchymal stem cells (1x105) cultivate in normal medium and chondrogenic medium for 
1, 3, 6 and 9 weeks were used for immunofluorescence. To conduct this experiment, we used 
cells from eGFP rats. Due to green GFP fluorescence, these cells were able to fluoresce under 
confocal microscopy (green) and we used others markers with red fluorescence. Initially, 
when we used to identify chondrogenic differentiation, we used markers from msenchymal 
stem cells (CD90, CD54and CD73), hematopoietic stem cells (CD45), cartilage-specific (type 
II collagen) and bone-specific (osteopontin). Cells were seeded in glass laminules. By 48 h, 
all cells were fixed with formaldehyde (2%) and stained with each antibody. Each well was 
washed with cold PBS 0,15M and the secondary antibodies (polyclonal anti-rat IgG made in 
rabbit, Molecular Probes) were applie and the cells were observed in confocal microscope 
(Soliman et al, 2008).  
2.5 3D scaffolds  
We developed two kinds of 3D scaffolds with similar chitosan (85% deacetylated, Sigma) 
and gelatin (Sigma) ratios. The difference between scaffolds is the reticulate use: 
glutaradehyde (0,1%, Sigma) or genipin (0,1%, Challenge Bioproducts). In order to solubilise 
chitosan we diluted it in acetic acidic (0,5mM) and gelatin was diluted in water. Misture of 
chitosan to gelatine was performed maintaining the ratio of 3 parts of chitosan solution to 1 
part gelatin solution. Immediately, we shook these solutions and distributed 1mL/well in 24 
wells plate. These plates were shaken in mechanic shaker overnight, protect from light. On 
the next day we added  1mL reticulate to each well. After 60min, these plates were frozen at 
-20°C overnight and then were transferred to -80°C. Plates were freeze-drying for 8 hours. 
The cilinders (3D scaffolds) were sterililzed (120°C) and used for cell culture (Guo et al, 2006 
and Yamane et al, 2005). The scaffolds were analyzed at the Department of Metallurgical 
and Materials Engineering, Federal University of Minas Gerais. The matrices were covered 
with gold (Sputter Coater - SPI Supplies) for 90 sec at 13mA. The images were obtained by 
means of scanning electron microscope (JEOL 6360LV), at 15kV and 750mA, to qualitatively 
assess the pore interconnectivity and size. 
2.6 Cell and 3D scaffold 
GFP cells were used because of the need to trace these cells; they were processed the same 
way as the MSC characterized by IMF. These cells were cultured in a 3D scaffold with 
chondrogenic medium for 3 weeks and surgically grafted in the rat subcutaneous dorsal 
region. After 6 weeks, all animals were dead and the samples were analyzed by IMF to 
verify presence of collagen type II. This assay was conducted because of the need to know 
whether differentiated cells can dedifferentiate after implantation (Janune et al, 2006). 
2.7 Statiscal analyzes  
All data are presented as an average ± standard deviation (SD). To test the significance of 
the observed differences between the study groups, a statistical evaluation was carried 
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out using a one-way ANOVA. A value of P< 0.05 was considered to be statistically 
significant. 
3. Results 
3.1 In vitro assay 
3.1.1 Cell characterization 
Cells were characterized by Immunofluorescence using GFP, MSC membrane surface 
markers CD90, CD73 and CD54, HSC surface marker, CD45 antibodies to show the absence 
of cell contamination with another source of stem cells. All cells were derived from GFP-
Lewis rats and verified with an anti-GFP primary antibody and PE (phicoerithrine) 
conjugate secondary antibody. Our results showed that all cells were positively for GFP 
(red, Fig. 1). For other markers, we used secondary antibodies with FITC (fluorecein 
isothiacyanate, Fig 1) and we observed that, cells were negative for CD45 and positive for 
CD90, CD73 e CD54. Nuclei were marked with DAPI (blue, Fig. 1). 
 
 
 
 
 
Fig. 1. Characterization of mesenchymal stem cells derived from adipose tissue of GFP-
Lewis rats. A- CD45, B-CD90,C CD73 and D-CD54. GFP: red, surface  marker: green and 
nucleus: blue. 
3.1.2 Cell differentiation 
In order to assess mesenchymal stem cell phenotype changes Cells differentiation was 
characterized by Immunofluorescence using membrane surface markers, CD90, CD73 and 
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CD54, MSC markers and CD45 a HSC marker. The goal of this experiment was to observe 
wether the cellular phenotype changed during the 9 weeks in chondrogenic medium. It is 
important to note that GFP cells are able to fluoresce without secondary antibody. Therefore 
anti-GFP were not used , only anti-CDs antibodies and secondary antibodies conjugated to 
PE to not GFP used. We observed that when cells were cultivated in chondrogenic medium, 
they were phenotypical alterated. Differentiated cells were positive for CD73 and Collagen 
II (red, Fig. 2) and they were negative for CD90, CD45, CD54 and osteocalcine (Fig. 2). 
 
 
 
 
 
Fig. 2. Cells differentiated with chondrogenic medium for 9 weeks. CD45, CD54, CD73, 
CD90, Collagen II and osteocalcine. Cells were GFP labeled. 
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3.2 Biomaterials 
3.2.1 Scaffold development and analysis 
The characterization of the biomaterials developed began at macroscopic aspects. In in one 
hand glutaraldehyde – reticulated scaffolds presented yellow color, genipin-reticulated 
scaffolds were dark blue. Microscopically, glutaraldeyde-reticulated matrices presented 
round pores with sizes ranging between 100 - 500 µm (Fig.  3A and 3C). On the other hand, 
genipin-reticulated matrices also presented pores with sizes between 100 - 500 µm, however 
these pores had the appearance of being more fine and fragile (Fig. 3 B and 3D). 
 
 
Fig. 3. 3D Scaffolds. (A) and (C) 3D scaffold with glutaraldehyde reticulates. (A) Without 
magnification and (C) SEM X100. (B) and (D) 3D scaffold with genipin reticulate. (B) 
Without magnification and (D) SEM X200. 
3.2.2 Scaffold and cells 
In order to assess the biomaterials’ citotoxicity, we seeded cells on the scaffold and verified 
if the cells were viable after 1 week. To verify this we performed a stablished citotoxicity 
assay called MTT, which verifies cell viability through the assessment of mitochondria 
function. It was possible then to verify that cells were kept viable in both scaffolds viable 
(Fig. 4). The cells colonized both scaffolds as shown in figure 5. Rat MSC extended 
pseudopodes to link onto wall scaffolds. 
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Fig. 4. Cells Viability (MTT). The graph shows cell viability when cultivated on scaffolds for 
1 week. 
 
 
Fig. 5. Scanning electronic microcopy. (A) and (B) Cells attached to scaffolds. 
3.3 In vivo assay 
After 3 weeks of culture in chondrogenic medium in respective scaffolds, we grafted those 
constructs (association of scaffolds and cells) subcutaneous onto the dorsal region of Lewis 
rats. Those rats were sacrificed with anesthestic overdose on the 3rd week after implantation. 
These samples were analyzed by immunofluorescence and we verified that collagen type II 
was present in both samples. This result showed that once cells differentiated in the scaffold 
they do not dedifferentiate. The cells were able to maintained the differentiated phenotype 
inside the scaffolds (Fig. 6). 
A B
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Fig. 6. Collagen II staining in vivo. Grafts of scaffolds with differentiated cells. (A) 
glutaraldehyde scaffold (B) Genipin scaffold. 
4. Discussion 
An ideal scaffold for been used in cartilage tissue engineering should be biodegradable, 
tissue compatible and display some degrees of rigidity and mechanical flexibility. It should 
have a three-dimensional configuration that provides a favorable environment for 
proliferation of chondrocytes and stem cells, and for cell migration and differentiation 
(Puppi et al, 2010 and Hutmacher et al, 2000). Furthermore, engineered bio-interfaces 
covered with biomimetic motifs, including short bioadhesive ligands, are a promising 
material-base strategy for tissue repair in regenerative medicine. 
A 3D culture system that promoted the chondrogenesis of MSCs was established in this 
study. It was observed that the combination of chitosan and gelatin scaffolds provided a 
supporting environment for the chondrogenesis of rat MSCs. The MSCs formed cartilage-
like tissue formation in vivo and in vitro via stimulation with common combinations of 
bioactive substances such as transforming growth factor (TGF-┚) and dexamethasone. The 
chondrogenic differentiation of MSCs is typically detected by the formation of cell spheres 
in culture expression type II collagen in the extracellular matrix, surface markers alteration 
and the confirmation of typical gene expressions profiles by PCR analysis as determined by 
Breyner and colleagues, 2010. 
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Thus, the chitosan-gelatin scaffold used in our work mimic the natural environment leading 
to increased ECM synthesis and promoting differentiation of MSCs to chondrocytes. 
Other publications have promoted variations in the matrix composition and GAG fine 
structure among the scaffolds used for cartilage tissue engineering in order to improve 
articular chondrocyte culture and chondrogenesis of progenitor cells (Mouw et al, 2005 and 
Melhorn et al, 2007). Our work, however, demonstrates that the 3D structure and chemical 
composition of the chitosan scaffolds and chondrogenic medium promoted MSC activation, 
proliferation and differentiation into chondrocytes, as was detected by a decrease in ALP 
production, an increase in collagen type II production and a lack of osteocalcin, a known 
osteogenic marker (Breyner et al, 2010; Huang et al, 2008 and Medrado et al, 2006). 
The 3D chitosan-gelatin structure is perhaps an indication that the attachment of MSCs to 
chitosan matrix could improve cell differentiation after matrix deposition as seen in the 
development of chondrocytes. One of the advantages of 3D systems is the substantial 
surface area to volume ratio can maximize cell-material contact when compared to 
monolayer culture systems. 
An ideal scaffold for cartilage tissue engineering should be biocompatible, non-cytotoxic and 
have favorable structural features for cell attachment and proliferation (Lefebvre et al, 1997 
and Mingliang et al, 2011). This study showed that cells attached, proliferated and secreted 
extracellular matrix in the two 3D porous scaffolds used. After 3 days in culture the viability 
and cell number in the 3D scaffold culture group had increased and was higher than that of 
the cells in monolayer culture treated with glutaraldehyde or genipin. The percentage of cells 
in different stages was determined by the MTT metabolization assay. Strong cell attachment 
and proliferation demonstrated that there was no cytotoxicity in either scaffolds used. The 
results agreed well with previous studies showing that initial cell adhesion was largely 
influenced of RGD in gelatin bound to chitosan (Dong et al, 2010). It was reported that 
immobilization of RGD peptide onto a scaffold enabled the adhesion of stem cells to the 
scaffold and inhibited the immediate matrix-induced cell aggregation (Re’em et al, 2010). It 
allowed better access for cells to nutrients, oxygen and chondrogenic inducer. TGF-┚1 is the 
main chondrogenic inducer during MSCs chondrogenesis (Barry et al, 2001). Studies 
suggested that RGD interaction with ┙5 and ┚1 integrin subunits enhanced TGF-┚1 secretion, 
and RGD-dependent integrin activation should be linked to modulation of TGF-┚1 activity 
(Ortega-Velasquez et la, 2003). In this study, the homogeneous spread of MSCs and abundant 
matrix secretion in scaffold indicated that TGF- ┚1 had efficiently induced MSCs 
chondrogenesis. These results may indicate that the 3D scaffold culture is superior to the 
monolayer culture because it is more effective in promoting ECM secretion or expression. 
The immunoflurescence staining also revealed type II collagen accumulation between 
scaffolds seeded with MSCs after in vivo implantation. It is also interesting to note that the 
3D culture system not only enhanced chondrogenesis but also increased the cell 
proliferation of MSCs. This may be a positive effect from chitosan-gelatin combination and 
TGF-┚ added to the chondrogenesis medium. 
Generally, cell attachment and spreading can occur in a serum-containing environment 
regardless of surface coating because many factors regulating cell adhesion and spreading, 
such as fibronectin, vitronectin, and cytokines are found in serum (Underwood et al, 2001). 
However, during in vitro chondrogenic differentiation of MSCs, defined chondrogenic 
differentiation inducing medium was used without serum. Therefore, cell adhesion was the 
vital step for MSCs chondrogenic differentiation. However, cell density strongly influences 
MSCs differentiation and cell-matrix secretion (Hui et al, 2008). 
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5. Conclusion 
Rat mesenchymal stem cells are able to differentiate when they are cultivated in 
chondrogenic medium. These cells can colonize scaffolds and differentiate inside them. 
Therefore, when these constructs were subcutaneously grafted in the rat dorsal region we 
verified that cells maintained a differentiated phonotype after 6 weeks. All together, we 
concluded that chitosan and gelatin are good candidates for scaffolds used to differentiate 
stem cells with chondrogenic treatment.  
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